This is the classic website, which will be retired eventually. Please visit the modernized ClinicalTrials.gov instead.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05565378
Recruitment Status : Recruiting
First Posted : October 4, 2022
Last Update Posted : February 21, 2024
Sponsor:
Collaborator:
iTeos Therapeutics
Information provided by (Responsible Party):
GlaxoSmithKline

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This study will evaluate the efficacy, safety, pharmacokinetics (PK), and pharmacodynamics (PDy) of novel immunotherapy combinations compared with immunotherapy monotherapy in participants with Programmed death ligand-1 (PD L-1) high (Tumor cells [TC]/ Tumor proportion score [TPS] ≥ 50%), previously untreated, unresectable, locally advanced or metastatic NSCLC. Drug name mentioned as Belrestotug, GSK4428859A, and EOS884448 are all interchangeable for the same compound. In the rest of the document, the drug will be referred to as Belrestotug.

Condition or disease Intervention/treatment Phase
Lung Cancer, Non-Small Cell Drug: Pembrolizumab Drug: Dostarlimab Drug: Belrestotug Drug: GSK6097608 Phase 2

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 300 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2, Randomized, Open-label, Platform Study Utilizing a Master Protocol to Evaluate Novel Immunotherapy Combinations in Participants With Previously Untreated, Locally Advanced/Metastatic, Programmed Death Ligand 1-Selected Non-Small-Cell Lung Cancer
Actual Study Start Date : October 14, 2022
Estimated Primary Completion Date : January 17, 2025
Estimated Study Completion Date : January 14, 2028

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lung Cancer
Drug Information available for: Dostarlimab

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Active Comparator: Pembrolizumab Monotherapy
Participants will be administered an intravenous (IV) infusion of pembrolizumab as monotherapy in a fixed dose.
 Drug: Pembrolizumab
Pembrolizumab will be administered as an IV infusion.
Experimental: Dostarlimab Monotherapy
Participants will be administered an IV infusion of dostarlimab as monotherapy in a fixed dose.
 Drug: Dostarlimab
Dostarlimab will be administered as an IV infusion.
Experimental: Substudy 1A
Participants will be administered an IV infusion of dostarlimab in a fixed dose followed by an IV infusion of belrestotug in a fixed dose (Dose A).
 Drug: Dostarlimab
Dostarlimab will be administered as an IV infusion.

Drug: Belrestotug
Belrestotug will be administered as an IV infusion.
Other Names:
  • EOS884448
  • GSK4428859A
Experimental: Substudy 1B
Participants will be administered an IV infusion of dostarlimab in a fixed dose followed by an IV infusion of belrestotug in a fixed dose (Dose B).
 Drug: Dostarlimab
Dostarlimab will be administered as an IV infusion.

Drug: Belrestotug
Belrestotug will be administered as an IV infusion.
Other Names:
  • EOS884448
  • GSK4428859A
Experimental: Substudy 1C
Participants will be administered an IV infusion of dostarlimab in a fixed dose followed by an IV infusion of belrestotug in a fixed dose (Dose C).
 Drug: Dostarlimab
Dostarlimab will be administered as an IV infusion.

Drug: Belrestotug
Belrestotug will be administered as an IV infusion.
Other Names:
  • EOS884448
  • GSK4428859A
Experimental: Substudy 2
Participants will be administered an IV infusion of dostarlimab in a fixed dose followed by an IV infusion of belrestotug along with IV infusion of GSK6097608 in a fixed dose.
 Drug: Dostarlimab
Dostarlimab will be administered as an IV infusion.

Drug: Belrestotug
Belrestotug will be administered as an IV infusion.
Other Names:
  • EOS884448
  • GSK4428859A

Drug: GSK6097608
GSK6097608 will be administered as an IV infusion.


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Objective Response Rate (ORR) [ Time Frame: Up to 24 months ]
    ORR, defined as the percentage of participants with complete response (CR) or partial response (PR) per RECIST 1.1 by investigator assessment.


Secondary Outcome Measures :
  1. ORR for comparison between experimental arms [ Time Frame: Up to 24 months ]
    ORR, defined as the percentage of participants with CR or PR per RECIST 1.1 by Investigator assessment.

  2. Progression free survival (PFS) [ Time Frame: Up to 24 months ]
    PFS is defined as the time taken from the date of randomization to the date of first documented progressive disease (PD) per RECIST 1.1 by investigator assessment or death due to any cause, whichever comes first.

  3. Overall survival (OS) [ Time Frame: Up to 5 years ]
    OS is defined as the time from the date of randomization to the date of death due to any cause.

  4. Duration of response (DOR) [ Time Frame: Up to 5 years ]
    DOR is defined as the time from the date of first documented objective response (CR or PR) to the date of first documented PD per RECIST 1.1 by investigator assessment or death due to any cause, whichever comes first.

  5. Number of participants with Treatment Emergent adverse events (TEAEs) and Adverse events of Special Interest (AESIs) [ Time Frame: Up to 5 years ]
    A TEAE is any event that was not present prior to the initiation of study intervention administration, or any event already present that worsens in intensity or frequency following exposure to study intervention. AESI are any AE (serious or non-serious) that is of scientific and medical concern specific to the study treatment and include infusion related reaction and immune-related adverse event (irAEs) from the date of enrollment to 90 days after last dose of study treatment.

  6. Number of participants with Serious adverse events (SAEs) [ Time Frame: Up to 5 years ]
    SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or any other situation according to medical or scientific judgment assessed by the investigator based on CTCAE v5.0 from the date of enrollment to 90 days after last dose of study treatment.

  7. Number of participants with TEAEs or SAEs leading to dose modifications (including dose delay and study intervention discontinuation) [ Time Frame: Up to 5 years ]
  8. Number of participants with positive antidrug antibodies (ADA) against belrestotug [ Time Frame: Up to 24 months ]
    Serum samples will be collected for the analysis of the presence of ADAs using validated immunoassays.

  9. Number of participants with positive antidrug antibodies (ADA) against dostarlimab [ Time Frame: Up to 24 months ]
    Serum samples will be collected for the analysis of the presence of ADAs using validated immunoassays.

  10. Number of participants with positive antidrug antibodies (ADA) against GSK6097608 [ Time Frame: Up to 24 months ]
    Serum samples will be collected for the analysis of the presence of ADAs using validated immunoassays.

  11. Maximum Observed Serum Concentration (Cmax) for belrestotug [ Time Frame: Up to 24 months ]
    Blood samples were collected for PK analysis of belrestotug.

  12. Maximum Observed Serum Concentration (Cmax) for dostarlimab [ Time Frame: Up to 24 months ]
    Blood samples were collected for PK analysis of dostarlimab.

  13. Maximum Observed Serum Concentration (Cmax) for GSK6097608 [ Time Frame: Up to 24 months ]
    Blood samples were collected for PK analysis of GSK6097608.

  14. Minimum Observed Serum Concentration (Cmin) for belrestotug [ Time Frame: Up to 24 months ]
    Blood samples were collected for PK analysis of belrestotug.

  15. Minimum Observed Serum Concentration (Cmin) for dostarlimab [ Time Frame: Up to 24 months ]
    Blood samples were collected for PK analysis of dostarlimab.

  16. Minimum Observed Serum Concentration (Cmin) for GSK6097608 [ Time Frame: Up to 24 months ]
    Blood samples were collected for PK analysis of GSK6097608.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically or cytologically confirmed diagnosis of locally advanced unresectable NSCLC not eligible for curative surgery and/or definitive radiotherapy with or without chemotherapy or metastatic NSCLC (squamous or non squamous)
  • No prior systemic therapy for their locally advanced or metastatic NSCLC
  • Provides a fresh tumor tissue sample or recent archival sample collected within 2 years prior to screening
  • PD-L1-high (TC/TPS ≥ 50%) tumor
  • Measurable disease based on RECIST 1.1, as determined by the investigator
  • Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1
  • Adequate baseline organ function
  • Female participants of childbearing potential must use adequate contraception

Exclusion Criteria:

  • Presence of Epidermal growth factor receptor (EGFR) mutations, Anaplastic lymphoma kinase (ALK) translocations, or other known genomic aberrations or oncogenic driver mutations for which a locally approved therapy is available. All participants with non squamous histology must have been tested for EGFR mutation and ALK translocation status
  • Had major surgery within 4 weeks or lung radiation of >30 grays (Gy) therapy within 6 months prior to the first dose of study intervention
  • Received prior therapy with any immune checkpoint inhibitors
  • Never smoker, defined as smoking <100 tobacco cigarettes in a lifetime
  • Has an invasive malignancy or history of invasive malignancy other than the disease under study within the last 5 years (clinical exceptions apply as per protocol)
  • Symptomatic, untreated, or actively progressing brain metastases and/or leptomeningeal disease (regardless of symptomatology, treatment status, or stability)
  • Autoimmune disease or syndrome that required systemic treatment within the past 2 years
  • Receiving any form of immunosuppressive medication
  • Received any live vaccine ≤ 30 days prior to first dose of study intervention
  • Any history of idiopathic pulmonary fibrosis, organizing pneumonia, drug induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis
  • History or evidence of cardiac abnormalities ≤6 months prior to enrollment
  • Current unstable liver or biliary disease
  • Severe infection within 4 weeks prior to randomization
  • Positive for tuberculosis, human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C
  • Has advanced, symptomatic, or visceral spread and is considered to be at imminent risk of life-threatening complications (including, but not limited to, massive uncontrolled effusions [e.g., pleural, pericardial, peritoneal])
  • Is currently participating in or has participated in a study of an investigational therapy within 4 weeks prior to the first dose of study intervention
  • Has a history of allogeneic tissue/stem cell transplant or solid organ transplant
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05565378


Contacts
Layout table for location contacts
Contact: US GSK Clinical Trials Call Center 877-379-3718 GSKClinicalSupportHD@gsk.com
Contact: EU GSK Clinical Trials Call Center +44 (0) 20 89904466 GSKClinicalSupportHD@gsk.com

Locations
Show Show 121 study locations
Sponsors and Collaborators
GlaxoSmithKline
iTeos Therapeutics
Investigators
Layout table for investigator information
Study Director: GSK Clinical Trials GlaxoSmithKline
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT05565378    
Other Study ID Numbers: 213824
2021-005115-32 ( EudraCT Number )
GALAXIES LUNG-201 ( Other Identifier: Study Identifier )
First Posted: October 4, 2022    Key Record Dates
Last Update Posted: February 21, 2024
Last Verified: February 2024
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: IPD for this study will be made available via the Clinical Study Data Request site.
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
Clinical Study Report (CSR)
Time Frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, a key secondary endpoints and safety data of the study.
Access Criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by GlaxoSmithKline:
Non-small cell lung cancer
Dostarlimab
Pembrolizumab
PD-L1
GSK4428859A
 EOS884448
PD-1 Inhibitor
Immunotherapy
Belrestotug
GSK6097608
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
 Carcinoma, Bronchogenic
Bronchial Neoplasms
Pembrolizumab
Dostarlimab
Antineoplastic Agents, Immunological
Antineoplastic Agents
Immune Checkpoint Inhibitors
Molecular Mechanisms of Pharmacological Action